Clinical Trial Update: Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of a pertuzumab biosimilar (PERT-IJS) versus EU-Perjeta, in combination with trastuzumab and carboplatin/doce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• HERCEPTIN (trastuzumab)
• PERT-IJS (pertuzumab biosimilar) (pertuzumab)
• Perjeta (pertuzumab)
• Taxotere (docetaxel)

Snippet

Sponsor: Biocon Biologics UK Ltd | Conditions: HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients | Phase 3 | Status: TERMINATED